TMS Therapy

Boise & Meridian

Learn more about NeuroStar TMS Therapy with the TMS Resource Guide


What is TMS Therapy?

TMS (Transcranial Magnetic Stimulation) uses a targeted pulse magnetic field, similar to what is used in an MRI (Magnetic Resonance Imaging) machine. While the patient is awake and alert, Neurostar TMS Therapy stimulates areas of the brain that are underactive in depression.

Indication for Major Depression Disorder

Indication for Major Depression Disorder

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. Our dedicated team is on standby to provide comprehensive information on how TMS therapy works, its benefits, and how it could be the transformative solution you’ve been searching for. Don’t let uncertainty deter you; take a step toward potential relief today. Give us a call or reach out online to find out more.

neurstar logo MidValley Healthcare Logo

MidValley Healthcare is a proud Neurostar TMS Provider

MidValley has met the NeuroStar Better Me Guarantee Pilot Program requirements!

NeuroStar uses transcranial magnetic stimulation (TMS) to target key areas of the brain that are underactive in people with depression. It is not ECT (electroconvulsive therapy). While the exact cause of depression is not known, the leading scientific theory is that it is caused by an imbalance of the brain’s neurotransmitters, which are chemical messengers that send signals between brain cells.

During a NeuroStar treatment session, a magnet similar in strength to that used in a magnetic resonance imaging (MRI) machine is used to stimulate nerve cells in the area of the brain thought to control mood. These magnetic pulses may have a positive effect on the brain’s neurotransmitter levels, making long-term remission possible.

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary. Visit for full safety and prescribing information.

There is no sedation, anesthesia, or recovery time and for most people the NeuroStar treatment is relaxing. The most common side effect is mild to moderate pain or discomfort at the treatment site that usually subsides within the first week of treatment.


FDA-cleared for OCD Treatment

In addition to treating Major Depression (MDD), NeuroStar TMS is now FDA-cleared for the treatment of obsessive-compulsive disorder (OCD) and anxious depression. Being non-drug and non-invasive, it doesn’t carry systemic side effects. To date, over 4 million treatments have been given using NeuroStar. For adults battling OCD, integrating NeuroStar’s TMS therapy with other treatments like medication or behavioral therapy can yield beneficial outcomes.

TMS Therapy Treatment for OCD

Treatment for OCD

Transcranial Magnetic Stimulation (TMS) therapy, once primarily known for its application in treating depression, has now gained FDA approval for the treatment of Obsessive-Compulsive Disorder (OCD). This groundbreaking development offers hope to millions suffering from the debilitating effects of OCD, especially those who haven’t found relief from traditional therapies and medications.

TMS therapy for the treatment of OCD involves using magnetic fields to stimulate nerve cells in the brain, targeting specific regions associated with mood and behavior. The approval for its use in treating OCD came after rigorous clinical trials showed significant reductions in obsessive-compulsive symptoms, with many participants experiencing relief from previously unmanageable compulsions.

How TMS Therapy Works

TMS Treatment Expectations

Insurance for TMS Treatment

A Major Burden for Society Today:

Looking at the entire world, we see that major depression is an enormous burden on society. In fact, in 2004 the World Health Organization rated unipolar major depression as the third most significant cause of disability worldwide…

*The World Health Organization. The World Health Report 2004: Changing History, Annex Table 3: Burden of disease in DALYs by cause. Geneva: WHO, 2004.

Current Drug Treatment Paradigm for Depression

There are a variety of first-line treatment options for major depression, which typically begins with the use of SSRIs. When these agents fail, treatment is typically to switch to a different antidepressant class, such as an MAOI or TCA. When these agents fail to provide benefit, the next treatment step is to move on to various augmentation strategies (such as adding Lithium or thyroid hormone) and, ultimately, to augmentation with an atypical antipsychotic . Clinicians may use a somewhat different treatment order, but in general, physicians begin this cascade of treatment attempts with a relatively simple antidepressant approach to obtain efficacy with minimal side effects. It is only when initial treatment fails, that physicians must move on to the more complex and, unfortunately, more toxic, drugs. This approach has certainly been shown to get many people well, and psychiatry has done a remarkable job employing these antidepressant agents.

depression therapy boise meridian

STAR*D Study demonstrates that current treatment has limited effectiveness

tms depression therapy boise

You may have experienced this lack of available, effective treatments for patients who have failed to benefit from initial antidepressant treatment. Let’s take a closer look at the evidence of the STAR*D study because it tells the same story. The design of this study involved four treatment Levels. These Levels were pre-specified by expert consensus, and were intended to reflect the general approach taken in clinical practice at the time STAR*D was constructed, which was about 10 years ago.

Likelihood of discontinuing treatment increases with each new medication attempt

tms depression treatment boise meridian

What the STAR*D study also shows, as shown here, is that while study discontinuation rates due to side effects is relatively low initially (about 9%), it rises very rapidly - nearly tripling in the transition from Level 1 (about 9%) to Level 2 (about 23%). Therefore, by the time patients had failed to benefit from three prior antidepressant treatments, nearly half of the patients discontinued further treatment due to adverse events.